The estimated Net Worth of Dennis M Brown is at least $4.27 Million dollars as of 25 July 2015. Dennis Brown owns over 10,000 units of DelMar Pharmaceuticals stock worth over $4,070,306 and over the last 11 years he sold DMPI stock worth over $0. In addition, he makes $200,000 as Chief Scientific Officer at DelMar Pharmaceuticals.
Dennis has made over 4 trades of the DelMar Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of DMPI stock worth $6,000 on 25 July 2015.
The largest trade he's ever made was buying 75,000 units of DelMar Pharmaceuticals stock on 22 July 2015 worth over $45,000. On average, Dennis trades about 3,448 units every 18 days since 2013. As of 25 July 2015 he still owns at least 3,037,542 units of DelMar Pharmaceuticals stock.
You can see the complete history of Dennis Brown stock trades at the bottom of the page.
Dr. Dennis M. Brown Ph.D. serves as Chief Scientific Officer of the Company. He also served as our director from February 11, 2013 to April 11, 2018. Dr. Brown is one of our founders and has served as Chief Scientific Officer and director of Del Mar (BC) since inception. Dr. Brown has more than thirty years of drug discovery and development experience. He has served as Chairman of Mountain View Pharmaceutical’s Board of Directors since 2000 and is the President of Valent. In 1999 he founded ChemGenex Therapeutics, which merged with a publicly traded Australian company in 2004 to become ChemGenex Pharmaceuticals (ASX: CXS/Nasdaq: CXSP), of which he served as President and a Director until 2009. He was previously a co-founder of Matrix Pharmaceutical, Inc., where he served as Vice President (VP) of Scientific Affairs from 1985-1995 and as VP, Discovery Research, from 1995-1999. He also previously served as an Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in Radiology at Stanford University Medical School. He received his B.A. in Biology and Chemistry (1971), M.S. in Cell Biology (1975) and Ph.D. in Radiation and Cancer Biology (1979), all from New York University. Dr. Brown is an inventor of many issued U.S. patents and applications, many with foreign counterparts.
As the Chief Scientific Officer of DelMar Pharmaceuticals, the total compensation of Dennis Brown at DelMar Pharmaceuticals is $200,000. There are 2 executives at DelMar Pharmaceuticals getting paid more, with Saiid Zarrabian having the highest compensation of $939,035.
Dennis Brown is 71, he's been the Chief Scientific Officer of DelMar Pharmaceuticals since 2018. There are no older and 6 younger executives at DelMar Pharmaceuticals.
Dennis's mailing address filed with the SEC is 12707 HIGH BLUFF DR., SUITE 200, SAN DIEGO, CA, 92130.
Over the last 11 years, insiders at DelMar Pharmaceuticals have traded over $104,000 worth of DelMar Pharmaceuticals stock and bought 663,835 units worth $651,854 . The most active insiders traders include John K Bell, Robert Hoffman und Jeffrey Bacha. On average, DelMar Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $20,766. The most recent stock trade was executed by John K Bell on 13 September 2019, trading 35,000 units of DMPI stock currently worth $23,800.
DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
DelMar Pharmaceuticals executives and other stock owners filed with the SEC include: